<DOC>
	<DOCNO>NCT02182050</DOCNO>
	<brief_summary>The overall purpose phase II trial evaluate efficacy 250 mg BIBF 1120 twice daily ( BID ) versus 150 mg BIBF 1120 BID patient advance non-small-cell lung cancer ( NSCLC ) fail least one prior chemotherapy regimen . In addition , safety data two different dosage collect analyse .</brief_summary>
	<brief_title>Efficacy Safety Oral Treatment With BIBF 1120 ES Advanced Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient histologically confirm advanced NSCLC ( i.e . adenocarcinoma , squamous cell carcinoma , large cell carcinoma , combination ) stage IIIB ( include pleural effusion ) stage IV . 2 . Patients recurrent disease relapse previous treatment platinum nonplatinum base chemotherapy . 3 . Full recovery therapy relate toxicity previous chemotherapy/ radiotherapy recovery much improvement may expect investigator . 4 . Age ≥18 year . 5 . Life expectancy least 3 month . 6 . ECOG performance score 0 , 1 2 . 7 . Unidimensionally measurable tumour lesion one technique , i.e . CT , MRI , Xray . 8 . Adequate hepatic function : total bilirubin within normal limit ; alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≤ 1.5x upper limit normal ( ULN ) patient without liver metastasis ; For patient liver metastasis : total bilirubin ≤ 1.5x ULN ; ALT and/or AST &lt; 2.5x ULN . 9 . Coagulation parameter : international normalised ratio le 1.3 prothrombin time ( PT ) partial thromboplastin time ( PTT ) less 1.5 time institutional ULN . 10 . Adequate renal function : serum creatinine ≤ 1.5 x upper normal limit . 11 . Absolute neutrophil count ( ANC ) ≥ 1500/mL , platelet ≥ 100000/mL , haemoglobin ≥ 9.0 g/dL . 12 . Written inform consent consistent ICHGCP guideline local law . Exclusion criterion : 1 . Active brain metastasis stable &lt; 4 week , symptomatic , require treatment anticonvulsant and/or steroid leptomeningeal disease . 2 . Patients history haemorrhagic thrombotic event ( include transient ischemic attack ) past 12 month . Known inherited predisposition thrombosis . 3 . Concurrent therapeutic anticoagulation ( except heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose daily acetylsalicylic acid &lt; 325mg ) . 4 . Sanguineous pleural effusion due disease pericardial effusion suspicious disease . 5 . Clinically significant haemoptysis ( 1 teaspoon ) within last 3 month . 6 . Centrally locate tumour radiographic evidence ( CT MRI ) local invasion major blood vessel . 7 . Radiographic evidence cavitary necrotic tumour screen . 8 . Major injury surgery . Planned surgical procedure trial . Patients incomplete wound heal within past 4 week . 9 . Gross haematuria within last 3 month . 10 . Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history myocardial infarction within past 6 month , serious cardiac arrhythmia , congestive heart failure accord New York Heart Association ( NYHA ) III IV . 11 . Serious illness concomitant nononcological disease neurologic , psychiatric infectious disease laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . 12 . Gastrointestinal abnormality would interfere intake absorption study drug , prior surgical procedure affect absorption , treatment peptic ulcer disease within last 6 month , active gastrointestinal bleeding unrelated cancer ( evidence either hematemesis , hematochezia , melena past 3 month without endoscopic document resolution ) , malabsorption syndrome . 13 . Other malignancy within past 5 year ( nonmelanomatous skin cancer cervical carcinoma situ ) . 14 . Treatment investigational drug ( elimination half life &lt; 5 day ) within past 4 week visit 2 participation another clinical trial within past 4 week start therapy ( visit 2 ) concomitantly trial . 15 . Treatment chemo , immuno , hormonotherapy biologic response modifier within past four week prior treatment trial drug trial . 16 . Radiotherapy within last 4 week prior start treatment trial drug radiotherapy area measurable disease . 17 . Hypersensitivity BIBF 1120 ES excipients trial drug . 18 . Male female patient sexually active unwilling use medically acceptable method contraception prior study entry duration study participation . 19 . Pregnancy breast feed . 20 . Known suspect active alcohol drug abuse . 21 . Patients unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>